Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | http://link.springer.com/article/10.1186/s40425-019-0792-9 |